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The objective of this study was to investigate the effect of docosahexaenoic acid (DHA) supplementation on blood and intestinal DHA
levels and lung function in mild/moderately affected adult CF patients with the DF508 genotype.
Background: Cystic Fibrosis (CF) patients often present with plasma fatty acid levels indicating low levels of linoleic (18 :2n6) and
docosahexaenoic (22 :6n3) acids and an increased level of arachidonic acid (20 :4n6). Improved dietary fat intake or reducing fat
malabsorption with pancreatic enzymes has failed to normalize this biochemical deficiency of DHA.
Methods: Five CF patients, aged 18–43, received 70 mg of DHA/kg body weight/d for six weeks. At baseline and at six weeks a physical
exam, lung function, 3-day dietary intake, duodenal mucosal biopsy and blood sample were assessed. The blood was analyzed for plasma
vitamin A, D and E levels, liver function tests, clinical chemistry (CBC, differential and electrolytes). Plasma and red blood cell fatty acid
levels were also analyzed. At three weeks, assessment included a physical exam, lung function test and fasting blood sample (vitamin levels,
liver function and clinical chemistry only).
Results: Pre- and post-measurements were compared for the four subjects who completed the study. An increase in DHA content (% w/w)
was observed in all phospholipid fractions of plasma, red blood cell and mucosal samples. No significant differences in vitamin levels, liver
function or lung function were observed.
Conclusions: The study proves the concept that an increase in tissue DHA levels in CF patients can be achieved by supplementing for six
weeks with 70 mg/kg/d DHA.
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Cystic fibrosis (CF) is the most common autosomal
recessive disorder in Caucasians. A defective gene encoding
the cystic fibrosis transmembrane conductance regulator
(CFTR) is causative for the disease. The basic defect
resulting from mutation of the CFTR gene is faulty
regulation of epithelial cell chloride channel. Over 1000
mutations in the CFTR gene have been identified, the most
common and severe of these mutations is a deletion of
phenylalanine at the amino acid position 508 (DF508) [1,2].
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pancreatic insufficiency. Thick mucous leads to increased
infection and subsequent inflammation in the lungs and
to malabsorption in the gastrointestinal tract via blockade
of pancreatic enzyme release. Current treatment includes
chest physical therapy and antibiotics for lung compli-
cations. Vitamin replacement and pancreatic enzymes
are provided as treatment to manage gastrointestinal
malabsorption.
Cystic fibrosis patients typically present with abnormal
fatty acid profiles, marked by normal to increased levels of
arachidonic acid (20 :4n6) and low levels of linoleic
(18 :2n6) and docosahexaenoic (22 :6n3) acids [3–6].
Docosahexaenoic acid (DHA) is an important component of
phospholipids in cell membranes. A biochemical deficiency
of DHA has been reported in blood lipid fractions and other
tissues in CF patients, particularly in patients with the
DF508 genotype [7–11]. Factors proposed to contribute to
this essential fatty acid status include reduced fat and energy
intake and fat malabsorption [3,6,9]. Failed attempts to
normalize fatty acid levels through improvements in dietary
fat intake [12–16] or minimizing fat malabsorption with
pancreatic enzymes suggests a problem in metabolism of
essential fatty acids and a potential requirement for
therapeutic doses of long chain polyunsaturated fatty acids
(LCPUFA) [6,7,17].
Kang et al. [18] proposed a relationship between
chloride transport and essential fatty acid metabolism
following observations that incorporation of essential fatty
acids into membrane phospholipids is influenced by
chloride channels. A more recent investigation considered
whether the DF508 mutation in the CFTR reduces
incorporation of linoleic acid into phospholipids of CF
cells [19]. This was elucidated through kinetic modeling of
time course data for incorporation of 14C-18 :2n6 into
control versus CF and DF508 CF cells. In control cells,
rate constants differed for incorporation of 14C-18 :2n6
into phospholipid and triacylglycerol. For CF cells, the rate
constants did not differ, suggesting a loss of metabolic
control in the CF cells. The authors suggest that a Ftrue_
essential fatty acid deficiency does not exist for CF, rather
the abnormal fatty acid profile likely results from impaired
intracellular utilization of linoleic acid [19].
Linolenic acid is the precursor for the long chain
polyunsaturated fatty acid DHA. Docosahexaenoic acid is
produced from linolenic acid by a series of elongation and
desaturation reactions, followed by beta-oxidation of
tetrahexaenoic acid to DHA. Beta-oxidation of the long
chain fatty acids is carried out in peroxisomes of cells [20].
A recent investigation looking at genotype in relation to
essential fatty acid deficiency noted that serum concen-
trations of docosahexaenoic acid were significantly lower
in individuals with severe CFTR mutations such as the
DF508 [21].
Research with essential fatty acid deficient (EFAD) CF
knockout mice (CFTR (/)) indicates an important rolefor DHA in correcting some of the imbalances found in
CF [22,23]. The membrane lipid imbalance, characterized
by increased AA and reduced DHA, was noted in organs
affected by CF, namely the ileum, pancreas and lung.
The fatty acid levels in lung and pancreas membrane
phospholipids of mice fed 40 mg/d DHA, were normal-
ized. The correction in fatty acid profile was accompa-
nied by positive morphological changes in the gastro-
intestinal tract and reversed the phenotypic expression of
CF.
The present investigation examines the effect of supple-
menting DF508 genotype adult CF patients with a dose of
70 mg DHA /kg body weight per day for six weeks. Effects
were measured through lung function and plasma and
duodenal mucosal DHA levels.2. Method
All procedures were approved by the Health Research
Ethics Board of the University of Alberta Hospitals.
2.1. Subjects
Informed consent was obtained from five individuals,
aged 18 to 43, with confirmed DF508 CF. Subjects were
recruited from the University of Alberta Hospital Cystic
Fibrosis Clinic. All were clinically stable with mild airflow
obstruction (FEV 51–79% predicted), a BMI >18, and taking
a minimum vitamin E dose (80 IU) for at least three months.
One subject was dropped from the study due to poor
compliance with DHA supplementation. The four subjects
completing the investigation, three males and one female,
averaged 36.5 years of age. The average weight was 64.6 kg,
the average height 165.3 cm and the average % ideal body
weight was 97.
2.2. Study design
Subjects were supplemented with oil capsules, contain-
ing 200 mg DHA per capsule (Martek Biosciences
Corporation, Columbia, MD). DHA was supplemented at
a dose of 70 mg/kg body weight/d for six weeks. The fatty
acid profile of the supplement was as follows: 14 :0
(14.74%), 16 : 0 (12.88%), 16 : 1 (1.76%), 18 : 1n9
(19.06%), 18 :3n3 (<0.05%), 20 :5n3 (<0.05%), 22 :
5n3 (0.33%), 22 : 6n3 (44.58%). Subjects were
instructed to take the capsules with meals. Compliance was
ensured by telephone contact and supplement counts. A
complete physical exam was done at baseline, 3 weeks and 6
weeks. Basic lung volume spirometry assessments, forced
vital capacity (FVC), forced expiratory volume (FEV1) and
maximal mid-expiratory flow rate (FEF25 – 75%) were
obtained at baseline, 3 weeks and 6 weeks. Fasting blood
samples were collected at baseline, 3 weeks and 6 weeks for
analysis of clinical chemistry, including CBC differential,
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partial thromboplastin time (PTT), INR, and fat soluble
vitamins (A, D and E) as well as liver function indicators:
serum albumin, alanine transaminase (ALT), g-glutamyl-
transferase (GGT) and alkaline phosphatase (ALP). Eight
hour fasting blood plasma phospholipid fatty acids were
assessed at baseline and 6 weeks. Fatty acid profile of
duodenal mucosal biopsy samples was obtained at baseline
and six weeks.
2.3. Duodenal biopsy
Duodenal tissue was obtained at baseline and six weeks
following an overnight fast. Subjects received Midazolam
and Demerol to achieve conscious sedation with comfort
during the endoscopic procedure. After being placed in a
lateral position, the patient had the endoscope passed
through the mouth, into the esophagus and advanced
through the stomach to the duodenum. Biopsy of the
mucosa was taken from the third portion of the duodenum.
Following the endoscopy, subjects were monitored until the
effects of sedation were absent. Biopsy samples were
immediately stored in liquid nitrogen at 70 -C until
analysis. The fatty acid profile and lipid composition was
subsequently determined.
2.4. Sputum collection and analysis
Sputum was collected and frozen in ethanol (1 g/4 ml)
at each visit. Typically samples ranged between 0.2 and 2
g. Samples were homogenized using a dounce homoge-
nizer then stored on ice for 30 min to precipitate proteins.
12-hydroxy stearate (5 Ag) was added as the internal
standard. The sample was centrifuged to pellet the residue
and the ethanol was transferred to a new tube and dried
under nitrogen and mild heating. The sample was
reconstituted in phosphate buffer (5 ml) and applied to a
Sep Pak C18 cartridge preconditioned with methanol (5
ml) and double distilled water (5 ml). The cartridge was
washed with 20% methanol in buffer before eluting with
methanol.
Total peptido-leukotrienes and leukotriene B4 were
converted to 5-hydroxy-eicosanoic acid (5-HEA) and
saturated LTB4, respectively, prior to derivitization for gas
chromatography–mass spectrometry (GC–MS) analysis.
Total peptido-leukotrienes were catalytically reduced and
desulphurized to 5-hydroxyeicosanoic acid (5-HEA) and
leukotriene B4 was reduced to 5,12-dihydroxyeicosanoic
acid [24]. These products were then derivatized to their
methyl ester, t-butyldimethylsilyl ether derivatives for GC–
MS analysis [25,26].
2.5. Dietary intake
At baseline and 6 weeks, a three-day dietary record was
collected to assess caloric, macronutrient (carbohydrate,protein, fat) and DHA intakes using Food Processor\
version 7.2 from ESHA Research (Salem, Oregon).
2.6. Separation of blood cells
Blood samples, drawn into EDTA Vacutainers\, were
centrifuged at room temperature (23-C) at 400 g for 10
min. The buffy coat and red blood cells were recovered and
diluted to 6 mL with 20g/L BSA (BSA fraction V; Sigma
Chemical Co., St. Louis, MO) in PBS (pH 7.4). Cell types
were separated on a two-layer ficoll gradient of Histopaque
1119 (Sigma Chemical Co.) [27]. After centrifugation at 700
g at 23 -C for 30 min, erythrocyte bands were recovered.
Cell fractions were washed twice with 10 mL of 20 g/L
BSA in PBS and centrifuged at 200 g at 4 -C for 10 min.
Erythrocyte membranes were prepared by the method of
Hanahan and Ekholm [28]. Briefly, erythrocytes were lysed
then centrifuged at 20,000 g for 40 min at 4 -C. The
supernatant was decanted, the pellet resuspended and
recentrifuged. The erythrocyte membranes washed once
more.
2.7. Lipid extraction and analyses
Lipids from plasma, erythrocyte and duodenal mucosa
biopsy were extracted by a modified Folch [29] using
chloroform :methanol (2 : 1 vol/vol) solution containing
0.05% ethoxyquin as an antioxidant. Phospholipid classes
were separated on silica H plates (Analtech, Newark, DE)
using a solvent system of chloroform/methanol /2-propa-
nol /0.25% wt/vol KCl / triethylamine (30 :9 :25 :6 :18 by
volume) [30].
2.8. Fatty acid analysis
Fatty acid methyl esters were prepared using 14% wt/wt
BF3 /methanol reagent [12]. Heptadecanoic acid was added
before methylation for quantification of the fatty acid
content of the plasma phospholipid fraction. Separation
and quantitation of fatty acid methyl esters was completed
using gas–liquid chromatography (Varian model 6000
equipped with a Vista 654 data system and a Vista 8000
autosampler; Varian Instruments, Georgetown, Ontario,
Canada) using a bonded fused silica BP20 capillary column
(25 m0.25 mm id) and quantitated using a flame
ionization detector [13]. Fatty acid content was calculated
on a percent wt/wt basis and also on a Ag/mL basis from the
known amount of standard added and determination of
appropriate response factors. Quantitation and identification
of peaks was based on relative retention times compared
with known standards.
2.9. Statistical analysis
Statistical analysis includes ANOVA for clinical measures
done at baseline, three weeks and six weeks. Bioavailability
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pre- and post-treatment results in fatty acids from plasma, red
blood cells and duodenal mucosal biopsy samples. Pre- and
post-results were analyzed by paired comparisons t-test
using SAS\ (SAS Institute Inc., NC). Differences were
considered significant at p <0.05.3. Results
3.1. Clinical observations
No treatment related serious adverse events were
reported. One subject was dropped from the final data set
for noncompliance. Normal range values for alanine
transaminase (<50 U/L), alkaline phosphatase (30–130
U/L), albumin (35–50 g/L), and gamma-glutamyltransfer-
ase (<70 U/L) were noted for three of the four CF subjects.
The fourth subject had an elevated GGT level (349 U/L),
with all other liver function tests within normal range.
Plasma vitamin levels (Vitamin A, Vitamin D, Vitamin E)
were within normal range (1.5–3.5 Amol/L, 25–200 nmol/
L and 12–45 Amol/L, respectively) and did not change
significantly (ANOVA) during the treatment period. No
change was observed in remaining blood parameters
analyzed (electrolytes, CBC and differential — data not
shown). No significant change in FVC, FEV1, or FEF was
noted.
3.2. Peptido-leukotrienes and LTB4
Analysis of pre and post sputum samples collected
from the CF patients in this clinical trial revealed the
presence of peptido-leukotrienes in only one of twelve
samples. LTB4 was not detected in any sample from this
group of CF patients.
3.3. Dietary analysis
Intakes at baseline compared to six weeks are as
follows: total energy=139T13.4 kJ/kg versus 157T17.6
kJ/kg; carbohydrate=50T 5.3% versus 46.1T6.8%; pro-
tein=20T1.73% and 18.2T1.8%, respectively; fat intake
averaged 28.8T3.2% and 35.5T4.0%, respectively. Al-0
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Fig. 1. DHA and AA Content (Ag/ml plasma) of total plasma phospholipids.
MeansTSE.though dietary fat intake increased from baseline to six
weeks, dietary DHA intake (supplement not included in
analysis) remained similar from baseline (0.05T0.02 g
DHA/d) to six weeks (0.04T0.02 g DHA/d). Thus, the
increase in tissue 22 :6n3 level observed in this study
was due to consumption of supplemental DHA and not to
dietary intake.4. Fatty acid content of plasma
4.1. Values reported in this section are meansTS.E
4.1.1. Total phospholipid
Comparisons of pre-supplementation values to post-
supplementation values showed no significant change for
18 :2n6 (pre=19.0T1.5; post=17.2T0.7) or 20 :4n6
(Fig. 1). A significant decrease in 18 :3n3 (pre=0.35T
0.02; post=0.27T0.03) and a significant increase in 22 :
6n3 was noted (Fig. 1).
4.1.2. Phosphatidylethanolamine
Observations of pre-DHA supplementation compared to
post-DHA supplementation showed a significant decrease in
18 :2n6 (pre=7.4T0.7; post=5.2T0.5) and 20 :4n6
(Fig. 2) in plasma phosphatidylethanolamine. The only
significant change noted for the omega-3 fatty acids was an
increase for 22 :6n3 (Fig. 2).
4.1.3. Phosphatidylcholine
In plasma phosphatidylcholine, the change in 18 :2n6
content (19.4T1.6; 17.4T1.3 0) was not significant in
pre- versus post-supplementation comparisons. A significant
decrease in 20 :4n6 was observed (Fig. 3). A decrease in
22 :5n3 (pre=0.6T0.2; post=0.3T0.1) and an increase in
22 :6n3 (Fig. 3) were the significant changes for omega-3
fatty acids in plasma phosphatidylcholine.5. Fatty acid composition of red blood cells
Values reported in this section are meansTS.E. All
results are reported as the effect of pre-DHA supplementa-
tion compared to post-DHA supplementation.Post
AA
DHA
*
*Significant difference ( p <0.05) between pre- and post-measurements.
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Fig. 2. DHA and AA content (%w/w) in phosphatidylethanolamine plasma, RBC and duodenal mucosa. *Significant difference ( p <0.05) between pre- and
post-measurements. Values are meansTSE (n =4).
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The decrease observed for 18 :2n6 (pre=8.4T0.9;
post=5.7T0.9) was significant. Other changes in red blood
cell total phospholipid fatty acids were not significant
(20 : 4n6 pre = 12.0 T1.6, post = 10.1 T2.8; 18 : 3n3
pre=0.1T0.03, post=0.1T0.02; 20 :5n3 pre=0.6T0.2,
post=0.8T0.3; 22 :6n3 pre=2.0T1.0, post=5.5T1.7).
5.2. Phosphatidylethanolamine
No change in 18 :2n6 was noted in red blood
cell phosphatidylethanolamine (pre=4.6T0.4; post=4.3T0
1
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Fig. 3. DHA and AA content (% w/w) in phosphatidylcholine plasma, RBC and du
post-measurements. Values are meansTSE (n =4).0.5). Decreased level of 20 :4n6 was observed (Fig.
2) but was not significant. No significant change
was observed in 18 :3n3 (pre=0.4T0.2; post=0.6T
0.1), or 20 : 5n3 (pre=1.0T0.4; post =1.7T0.4).
22 :6n3 increased, but not statistically significant
(Fig. 2).
5.3. Phosphatidylcholine
No change in 18 :2n6 was noted in red blood cell
phosphatidylcholine (pre=14.9T2.8; post=13.6T1.0). De-
creased 20 :4n6 was observed (Fig. 3) but was not
significant. No significant change was observed inDHA-Pre
DHA-Post
AA-Pre
AA-Post
*
Duodenal-
AA
Duodenal-
AA
odenal mucosa. *Indicates significant difference ( p <0.05) between pre- and
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(0.3T0.1; 1.3T0.4). 22 :6n3 increased (Fig. 3).
6. Fatty acid composition of duodenal mucosal samples
Values reported in this section are meansTS.E. All
results are pre-DHA supplementation values compared to
post-DHA supplementation values.
6.1. Total phospholipid
No significant change in 18 : 2n6 (pre=16.7T0.5;
post = 18.2 T1.6) or 20 : 4n6 (pre = 6.7 T0.5; post =
5.8T0.7) was noted in total phospholipid from intestinal
mucosa. No change was noted in 18 :3n3 (pre=0.2T0.03;
post=0.2T0.02). The increase in 20 :5n3 (pre=0.4T0.1;
post = 1.1 T0.4) and 22 : 6n3 (pre = 0.6 T0.1; post =
3.1T1.6) was not significant.
6.2. Phosphatidylethanolamine
18 :2n6 was significantly reduced in mucosal phos-
phatidylethanolamine (pre=13.0T0.8; post=9.8T1.4). No
significant change was noted for 20 :4n6 (Fig. 2), or
20 :5n3 (pre=1.0T0.1; post=1.9T0.5). The increase in
22 :6n3 was significant (Fig. 2).
6.3. Phosphatidylcholine
No significant change in 18 : 2n6 (pre=19.4T2.5;
post=19.6T2.4), 20 :4 n6 (Fig. 3), 18 :3 n3 (pre=
0.2T0.01; post=0.2T0.03), or 20 :5n3 (pre=0.4T0.1;
post=1.0T0.2) was observed in mucosal phosphatidylcho-
line. The increase in 22 :6n3 was significant (Fig. 3).7. Discussion
Low levels of linoleic acid in CF subjects can be increased
via n6 supplementation [14–16,31,32], but at the cost of a
reduction in DHA level [15]. DHA supplementation resulted
in generally little change in 18 :2n6 levels except that
18 :2n6 was reduced significantly in plasma and mucosa
phosphatidylethanolamine as well as red blood cell total
phospholipid.
Low levels of linoleic acid might be expected to reduce
eicosanoid production. Compared to normal subjects how-
ever, CF patients appear to have a greater synthesis of
certain eicosanoids and prostaglandins (thromboxane A2
and PGF2a´) [33–35]. The inflammatory marker, LTB4, had
previously been reported to be reduced in serum following
n3 supplementation [36], but not affected by oral
administration (40 mg/d) of DHA in an animal model
[41]. Although LTB4 was not detected in sputum samples
collected from this group of individuals, it is noted that these
subjects were considered ‘‘well’’ and thus exhibited minimalinflammation. Subjects for this investigation had to be
‘‘well’’ in order to undergo the endoscopic procedure at
baseline and at six weeks. In all clinical measures and lung
function parameters, no significant changes were observed.
These observations also may be related to the overall
‘‘wellness’’ of the individuals selected for this study as well
as to the short course of supplementation. A recent
Cochrane review [42] concluded that supplementation of
n3 fatty acids ‘‘may provide some benefits for CF patients
with relatively few adverse effects.’’ It was suggested,
however, that ‘‘the evidence, so far, is insufficient to draw
firm conclusions’’ [42].
‘‘Genetic background and age may have an overriding
effect on essential fatty acid status,’’ as recently indicated by
Werner et al. [43]. This research group examined in vivo
analysis of long chain polyunsaturated fatty acid synthesis
in a mouse model for CF. Although the authors found that
EFA were adequately absorbed and metabolized in cftr/
CAM mice and concluded that a ‘‘membrane imbalance is
not inextricably linked to the CF genotype,’’ their results
imply that sufficient oral EFA intake may effectively
prevent compromised EFA status in CF. In another mouse
model, Dombrowsky et al. [44] also found no deficiency of
22 :6n3 in any phospholipid class from lung, pancreas
and liver. This group concluded that different mouse models
of CF contain variable membrane phospholipid composi-
tions. Perhaps more importantly, it should be noted that the
mouse has significantly lower EFA requirements than the
human. This begs the question as to whether a mouse model
with a defective CFTR gene or a knockout can be expected
to show the same EFA deficiency symptoms as the human
with a defective CFTR gene.
Membrane lipids in organs affected by CF are character-
ized by increased arachidonic acid and reduced DHA [37–
40]. In the current investigation, arachidonic acid levels
generally decreased in all measured phospholipid fractions of
plasma, red blood cells and intestinal mucosal samples
following supplementation with DHA. The decrease reached
significance in plasma phosphatidylcholine and phosphati-
dylethanolamine. In comparison, tissueDHA levels improved
as a result of DHA supplementation. In general, the content of
DHA in plasma, red blood cells and intestinal mucosa
increased following supplementationwithDHA.The increase
was significant in all phospholipid fractions of plasma. The
increase DHA level was also significant in phosphatidyleth-
anolamine and phosphatidylcholine of duodenal mucosal
biopsy samples. Despite the small sample size and the overall
‘‘wellness’’ of the subjects in this investigation, the results
imply that a dose of 70 mg/kg body weight/d DHA over a
six week period is sufficient to significantly improve DHA
levels in DF508 CF patients. With a larger number of
subjects, a longer duration of supplementation, and a ‘‘less-
well’’ group, the pulmonary function results may demon-
strate benefit. Theoretically correcting the membrane lipid
imbalance in the organs affected by CF, could significantly
improve quality of life for these individuals. In summary,
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DHA can achieve desirable changes in DHA content in all
phospholipid fractions of plasma, red blood cells and
intestinal mucosal samples.References
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